Publications by authors named "F Manguso"
Background: Non-variceal upper gastrointestinal bleeding is a common gastroenterological emergency associated with significant morbidity and mortality. Upper gastrointestinal endoscopy is currently recommended as the gold standard modality for both diagnosis and treatment. As historically played a limited role in the diagnosis of acute non-variceal upper gastrointestinal bleeding, multidetector-row computed tomography angiography is emerging as a promising tool in the diagnosis of non-variceal upper gastrointestinal bleeding, especially for severe cases.
View Article and Find Full Text PDFAims: This study aims to evaluate the prognostic impact of the arrhythmogenic substrate size in symptomatic Brugada syndrome (BrS) as well as to validate the long-term safety and effectiveness of epicardial radiofrequency ablation (RFA) compared with no-RFA group.
Methods And Results: In this prospective investigational long-term registry study, 257 selected symptomatic BrS patients with implantable cardioverter defibrillator (ICD) implantation were included. Among them, 206 patients underwent epicardial RFA and were monitored for over 5 years post-ablation (RFA group), while 51 patients received only ICD implantation declining RFA.
Background: Vedolizumab registration trials were the first to include elderly patients with moderate-to-severe ulcerative colitis (UC) or Crohn's disease (CD), but few real-life data have been reported in this population.
Aims: We investigated the effectiveness and safety of vedolizumab in matched cohorts of elderly and nonelderly UC and CD patients.
Methods: The Long-term Italian Vedolizumab Effectiveness (LIVE) study is a retrospective-prospective study including UC and CD patients who started vedolizumab from April 2016 to June 2017.
Article Synopsis
- The study compared the effectiveness of ustekinumab and vedolizumab as second-line treatments for Crohn's disease in patients who did not respond to TNF inhibitors, with outcomes assessed through clinical measures and imaging techniques.
- Results showed no significant differences in clinical outcomes at 26 weeks, but at 52 weeks, vedolizumab performed better with higher rates of clinical remission (55.5% vs 42.5%) and steroid-free remission (51.1% vs 40.6%).
- Both treatments had similar safety profiles, and clinical responses at 26 weeks were predictive of later steroid-free remission for both medications.